FDA approves amivantamab-vmjw with carboplatin and …
WEBOn September 19, 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small...
RYBREVANT® (amivantamab-vmjw) plus standard of care …
WEBSep 17, 2024 — RYBREVANT ® (amivantamab-vmjw), a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity, is approved in the U.S., Europe, and in other markets around the world as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by ...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) …
WEBAug 20, 2024 — RYBREVANT ® is approved in the U.S. in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
FDA approves amivantamab-vmjw for EGFR exon 20 insertion …
WEBOn March 1, 2024, the Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment of locally advanced or...
FDA approves lazertinib with amivantamab-vmjw for NSCLC
WEBAug 20, 2024 — Lazertinib with amivantamab demonstrated a statistically significant improvement in PFS compared to osimertinib with a hazard ratio of 0.70 (95% confidence interval [CI]: 0.58, 0.85;...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows …
WEBSep 14, 2024 — RYBREVANT ® (amivantamab-vmjw), a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity, is approved in the U.S., Europe, and in other markets around the world as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an ...
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 …
WEBOct 21, 2023 — Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease...
RYBREVANT® (amivantamab) plus lazertinib shows longer
WEBMay 31, 2024 — RYBREVANT® (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer...
RYBREVANT® (amivantamab-vmjw) in Combination With …
WEBMar 1, 2024 — National Comprehensive Cancer Network ® (NCCN ®) updated its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) to recommend amivantamab-vmjw (RYBREVANT®) plus chemotherapy as a...
Amivantamab plus Lazertinib in Previously Untreated
WEBJun 26, 2024 — Amivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal...